Immatics (IMTX) Reports Q1 Loss, Tops Revenue Estimates

Immatics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $32.87 million for the quarter ended March 2024, surpassing the Zacks Consensus Estimate by 85.05%. This compares to year-ago revenues of $10.65 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's ...